{"id":"probucol-and-cilostazol","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Tachycardia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Probucol acts as a potent antioxidant that reduces LDL cholesterol oxidation and improves HDL cholesterol levels, while cilostazol inhibits phosphodiesterase-3 to increase cAMP levels in platelets and vascular smooth muscle, resulting in antiplatelet effects, vasodilation, and improved blood viscosity. Together, they address multiple pathways in atherosclerotic cardiovascular disease and peripheral arterial disease.","oneSentence":"This combination of probucol (an antioxidant lipid-lowering agent) and cilostazol (a phosphodiesterase-3 inhibitor with antiplatelet and vasodilatory properties) works synergistically to reduce lipid oxidation, improve blood flow, and inhibit platelet aggregation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:02:45.025Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyperlipidemia and atherosclerotic cardiovascular disease"},{"name":"Peripheral arterial disease"}]},"trialDetails":[{"nctId":"NCT02098460","phase":"PHASE4","title":"To Compare the Effect of Concomitant Administration of Probucol and Cilostazol With Probucol Single Treatment on the Atherosclerosis Related Markers (Including the Thickness of the Achilles Tendon) and Evaluate Safety (Based on Atorvastatin Treatment) in Severe Hypercholesterolemia Subject","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2013-10","conditions":"Severe Hypercholesterolemia","enrollment":300},{"nctId":"NCT00823849","phase":"PHASE4","title":"Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2008-10","conditions":"Type 2 Diabetes Mellitus, Arteriosclerosis Obliterans","enrollment":200},{"nctId":"NCT01142284","phase":"PHASE2","title":"Evaluation of Concomitant Administration of Cilostazol and Probucol on Biomarkers, Endothelial Function and Safety","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2010-05-19","conditions":"Peripheral Artery Disease","enrollment":80},{"nctId":"NCT00549978","phase":"PHASE4","title":"Safety and Pharmacokinetics of Probucol and Cilostazol","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2007-10","conditions":"Healthy","enrollment":32},{"nctId":"NCT01291641","phase":"PHASE4","title":"Effect of Probucol and/or Cilostazol on Mean IMT in Patients With Coronary Heart dIsease","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2011-03","conditions":"Hyperlipidemias","enrollment":342},{"nctId":"NCT02483169","phase":"PHASE4","title":"PreventIon of IMT Progression in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage-IMT Study","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2009-06","conditions":"Brain Ischemia, Intracranial Hemorrhages","enrollment":800},{"nctId":"NCT01013532","phase":"PHASE4","title":"PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2009-06","conditions":"Brain Ischemia, Intracranial Hemorrhages","enrollment":1600},{"nctId":"NCT01252056","phase":"PHASE4","title":"A Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2010-03","conditions":"Diabetic Nephropathy","enrollment":353},{"nctId":"NCT01031667","phase":"PHASE4","title":"Synergistic Effect of Combination Therapy With Cilostazol and Probucol on Plaque Stabilization and Lesion Regression: Serial Intravascular Ultrasound and Virtual Histology Study(SECURE Study)","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2009-11","conditions":"Therapy","enrollment":118},{"nctId":"NCT00823875","phase":"PHASE4","title":"Study of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2009-03","conditions":"Atherosclerosis Cerebral Infarction","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":30,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Probucol and Cilostazol","genericName":"Probucol and Cilostazol","companyName":"Otsuka Beijing Research Institute","companyId":"otsuka-beijing-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination of probucol (an antioxidant lipid-lowering agent) and cilostazol (a phosphodiesterase-3 inhibitor with antiplatelet and vasodilatory properties) works synergistically to reduce lipid oxidation, improve blood flow, and inhibit platelet aggregation. Used for Hyperlipidemia and atherosclerotic cardiovascular disease, Peripheral arterial disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}